US4070483A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of administering a human ocular treating agent and product therefor
Assignee: Individual
•
Filing: 1976-06-21
•
Granted: 1978-01-24
•
Expires: 1996-06-21
Abstract
Abstract A method of administering an agent to the ocular lens of animals for the treatment of an aging parameter and nuclear cataracts therein which includes the steps of preparing a solution of D,L-penicillamine; exposing an artificial ocular contact lens to the solution such that the compound is retained on the artificial lens; and contacting the animal lens with the artificial lens so that the compound is absorbed into the animals lens. Another method is to incorporate the compound in a timed-release carrying agent and place the agent in the inferior cul de sac of the eye.
Inventors
- 👤 Sidney Lerman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 12:52
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0048; A61K9/0051
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
97 words
A method of administering an agent to animal ocular lenses for the treatment of nuclear cataracts therein, comprising the steps of: a. preparing a solution which is isotonic with animal tears and which includes physiological saline and an effective amount of said agent to form a saturated solution, said agent being D,L-penicillamine; b. exposing artificial ocular contact lenses to said solution for a sufficient period of time wherein said agent is retained on said lenses; and c. placing said exposed artificial lenses on the ocular cornea and/or cornea and sclera whereby said agent enters said ocular lenses.
Claim 2
Independent Claim
97 words
A method of administering an agent to animal ocular lenses for the treatment of nuclear cataracts therein, comprising the steps of: a. preparing a solution which is isotonic with animal tears and which includes physiological saline and an effective amount of said agent to form a saturated solution, said agent being D,L-penicillamine; b. exposing artificial ocular contact lenses to said solution for a sufficient period of time wherein said agent is retained on said lenses; and c. placing said exposed artificial lenses on the ocular cornea and/or cornea and sclera whereby said agent enters said ocular lenses.
Claim 3
Dependent Claim
24 words
A method as claimed in claim 1 wherein said solution further includes an antiseptic material in the range of 0% to 0.5% by weight.
Claim 4
Dependent Claim
18 words
A method as claimed in claim 2 wherein the preferred amount of said material is 0.05% by weight.
Claim 5
Dependent Claim
17 words
A method as claimed in claim 3 whereby said material is the sodium salt of ethylmercurithiosalicylic acid.
Claim 6
Independent Claim
48 words
A method of administering an agent to animal ocular lenses for the treatment of the formation of nuclear cataracts therein, comprising the steps of incorporating an effective amount of D,L-penicillamine in a sustained release carrier and placing said carrier within the inferior cul de sac of the eye.
Claim 7
Independent Claim
48 words
A method of administering an agent to animal ocular lenses for the treatment of the formation of nuclear cataracts therein, comprising the steps of incorporating an effective amount of D,L-penicillamine in a sustained release carrier and placing said carrier within the inferior cul de sac of the eye.
Claim 8
Dependent Claim
23 words
A method as claimed in claim 5 wherein said carrier releases said agent at a rate of from 1 - 10 mg/24 hours.
Claim 9
Dependent Claim
42 words
An ocular lens treatment composition for animals, comprising an effective amount of D,L-penicillamine and a sustained release carrier therefor in a form for placement in the inferior cul de sac of the eye for the treatment of nuclear cataracts in said lens.
Claim 10
Dependent Claim
42 words
An ocular lens treatment composition for animals, comprising an effective amount of D,L-penicillamine and a sustained release carrier therefor in a form for placement in the inferior cul de sac of the eye for the treatment of nuclear cataracts in said lens.
Claim 11
Independent Claim
22 words
A method of treating nuclear sclerosis in animals comprising the step of administering to the ocular lens an effective amount of D,L-penicillamine.
Claim 12
Independent Claim
22 words
A method of treating nuclear sclerosis in animals comprising the step of administering to the ocular lens an effective amount of D,L-penicillamine.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-01-23 | 1981-07-25 | 1982-01-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-01-23 | 1985-07-25 | 1986-01-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-01-23 | 1989-07-25 | 1990-01-24 | $7700.00 | Window Closed / Lapsed |